Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma
文献类型：期刊论文
| 作者 | Girard, N; Sima, CS; Jackman, DM; Sequist, LV; Chen, H; Yang, JCH; Ji, H; Waltman, B; Rosell, R; Taron, M |
| 刊名 | EUROPEAN RESPIRATORY JOURNAL
 |
| 出版日期 | 2012 |
| 卷号 | 39期号:2页码:366-372 |
| 关键词 | Adenocarcinoma epidermal growth factor receptor mutations lung cancer nomogram prediction score tyrosine kinase inhibitor |
| 通讯作者 | Girard, N (reprint author), Hop Louis Pradel, Serv Pneumol U80, 28 Ave Doyen Lepine, F-69677 Bron, France.,nicolas.girard@chu-lyon.fr |
| 英文摘要 | Epidermal growth factor receptor (EGFR) tumour genotyping is crucial to guide treatment decisions regarding the use of EGFR tyrosine kinase inhibitors in nonsmall cell lung cancer (NSCLC). However, some patients may not be able to obtain tumour testing, either because tissue is limited and/or tests are not routinely offered. Here, we aimed to build a model-based nomogram to allow for prediction of the presence of EGFR mutations in NSCLC. We retrospectively collected clinical and pathological data on 3,006 patients with NSCLC who had their tumours genotyped for EGFR mutations at five institutions worldwide. Variables of interest were integrated in a multivariate logistic regression model. In the 2,392 non-Asian patients with lung adenocarcinomas, the most important predictors of harbouring EGFR mutation were: lower tobacco smoking exposure (OR 0.41, 95% CI 0.37-0.46), longer time interval between smoking cessation and diagnosis (OR 2.19, 95% CI 1.71-2.80), advanced stage (OR 1.58, 95% CI 1.18-2.13), and papillary (OR 4.57, 95% CI 3.14-6.66) or bronchioloalveolar (OR 2.84, 95% CI 1.98-4.06) histologically predominant subtype. A nomogram was established and showed excellent discriminating accuracy: the concordance index on an independent validation dataset was 0.84. As clinical practices transition to incorporating genotyping as part of routine care, this nomogram could be highly useful to predict the presence of EGFR mutations in lung adenocarcinoma in non-Asian patients when mutational profiling is not available or possible. |
| 学科主题 | Respiratory System |
| 类目[WOS] | Respiratory System |
| 关键词[WOS] | FACTOR-RECEPTOR MUTATIONS ; SOMATIC MUTATIONS ; NEVER-SMOKERS ; CANCER ; GEFITINIB ; GENE ; CHEMOTHERAPY ; SUBTYPES |
| 收录类别 | SCI |
| 语种 | 英语 |
| WOS记录号 | WOS:000300411400020 |
| 版本 | 出版稿 |
| 源URL | [http://202.127.25.143/handle/331003/548]  |
| 专题 | 上海生化细胞研究所_上海生科院生化细胞研究所 |
| 推荐引用方式 GB/T 7714 | Girard, N,Sima, CS,Jackman, DM,et al. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma[J]. EUROPEAN RESPIRATORY JOURNAL,2012,39(2):366-372. |
| APA | Girard, N.,Sima, CS.,Jackman, DM.,Sequist, LV.,Chen, H.,...&Pao, W.(2012).Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma.EUROPEAN RESPIRATORY JOURNAL,39(2),366-372. |
| MLA | Girard, N,et al."Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma".EUROPEAN RESPIRATORY JOURNAL 39.2(2012):366-372. |
入库方式： OAI收割
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。